Oh look another final interjection, how can we believe you when you said you were going but you're still here?
Sanders is also not good for America in general unless you want us to become another Europe and keep about 25% of what you earn while the government provides everything for you. Check his plans and how much they cost vs his tax increases. There's a real shortfall in revenues, ie more deficit spending.
Bloomberg doesn't have a chance in heck, even the Dems can't stand his attack on the 2nd amendment and sugar products. Unelectable unless you only count the votes from NYC,LA and San Fran.
So you don't believe the latest guidance for approx 90 million in expenses this year. You have to go up 50% and completely strain all credibility.
I am starting to come to that conclusion too except he doesn't start and run his own 100 post topic. However he has posted 380 plus times since Jan 1. Who has that much time on his hands?
Yes they are due a $2 million milestone payment for EU approval. I'll assume it was made in the 4th quarter but we'll see when the Q4 earnings are released.
From the last 10Q
NOTE 5 - LICENSE AGREEMENTS
In November 2005, we entered into a license agreement with Panion & BF Biotech, Inc. (“Panion”). Under the license agreement, we acquired the exclusive worldwide rights, excluding certain Asian-Pacific countries, for the development and marketing of ferric citrate. To date, we have expensed an aggregate of $11.6 million of milestone payments to Panion, including a milestone payment of $2.0 million due upon our successful achievement of European marketing approval in September 2015. In addition, Panion is eligible to receive royalty payments based on a mid-single digit percentage of net sales of Auryxia. For the three and nine months ended September 30, 2015, we recorded approximately $189,000 and $316,000, respectively, in cost of goods sold related to royalty payments due Panion relating to sales of Auryxia (ferric citrate) in the U.S.
Any questions...... Baupost and the cabal have your answers.... and your money. ;-)
I'll take whatever gets us to $20 minimum. I have time but would obviously prefer something in the next year rather than YEARS.
Scripts are back to where they were before the 3 week Holiday Season. But you're right we're talking about 10's of scripts when we should be talking about 100's of scripts
I'm patiently waiting for the Q4 conference call to see what the Specialty scripts were and 2016 guidance. Yahoo has the earnings date between 2/25 and 2/29. And of course news about the EU and Japan sales.
I have plenty of time, it's all about the long game.
8% below best numbers seen week of 12/4 and 12/18 not 20% and in line with 12/11 week. Not happy with them but at least it's not going backwards. Come on IDA study results.
24 weeks included the safety extension
From Clinical Trials dot gov
a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period ("Randomized Period"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) ("Extension Period").
Wait, you're forgetting all the money he made shorting it down from $15, at worst he's even. Thanks RI for that ammunition.